 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Noludar, Dimerin, Noctan, Methyprylone, Noctan |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | 60% |
| Eliminationhalf-life | 6-16 hours |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.004.315 |
| Chemical and physical data | |
| Formula | C10H17NO2 |
| Molar mass | 183.251 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
 N Y (what is this?) (verify) | |
Methyprylon, orNoludar, is asedative/tranquilizer andhypnotic central nervous system depressant of thepiperidinedionederivativechemical class, first developed in the 1940s byHoffmann-La Roche.[2]This medicine was used for treatinginsomnia, but is now rarely used as it has been replaced by newer drugs with fewer side effects, such asbenzodiazepines.[3]
Methyprylon was withdrawn from the US market in June 1975 and the Canadian market in September 1990.Some other trade names are Noctan and Dimerin.
Side effects can include
A study of single oral doses of 300 mg in healthy volunteers found that the zero-order absorption model fit the data best. Mean (+/- SD) values for the half-life (9.2 +/- 2.2 h), apparent clearance, (11.91 +/- 4.42 mL/h/kg) and apparent steady-state volume of distribution, (0.97 +/- 0.33 L/kg) were found.[4]
A case report found that the pharmacokinetics of methyprylon were not concentration dependent in an overdose case; explanations included saturation or inhibition of metabolic pathways. The generally accepted half-life for a therapeutic dose was not found appropriate in intoxicated patients and would underestimate the time required to reach a safe concentration of the drug.[5]